Skip to main content

Royalty Pharma Announces Inaugural Prize for Impact in Healthcare

Written by Customer Service on . Posted in Public Companies.

  • Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate Cancer Foundation
  • The Prize includes a charitable donation to further fund medical research

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or organizations who positively impact healthcare, was awarded to Micheal Milken. The prize includes a $250,000 charitable donation to support medical research or educational initiatives that further the recipient’s work.

“I am delighted to award the inaugural Royalty Pharma Prize for Impact in Healthcare to Michael Milken,” said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. “Mike has made a tremendous global impact in the fields of medical research and public health through his work at the Milken institute, Faster Cures and the Prostate Cancer Foundation.”

Michael Milken is the founder and chairman of the Milken Institute, an independent, nonprofit, nonpartisan economic think tank that publishes research and hosts conferences that apply market-based principles and financial innovations to social issues in the US and internationally.  Mr. Milken is also the founder of the Prostate Cancer Foundation (PCF). Since its inception in 1993, the PCF has raised over $1 billion to support prostate cancer research with funding allocated to more than 2,240 research projects across 245 leading cancer centers in 28 countries. Notably, the PCF has been instrumental in the approval of six new drugs by the FDA for advanced prostate cancer, improving patients’ quality of life and contributing to the decline in prostate cancer mortality rates over the past two decades. 

Royalty Pharma focuses its philanthropy on non-profit institutions and initiatives that enable innovation in life sciences, reduce the risk of disease, and strengthen and ensure equal access to healthcare. In 2022, Royalty Pharma announced a charitable contribution to Icahn Mount Sinai’s Institute for Health Equity Research (IHER) and the creation of the Mount Sinai-Royalty Pharma Alliance for Health Equity Research to support IHER in its ongoing efforts to close the health care disparity gap and translate discoveries into sustainable, scalable initiatives and policies that break down systemic barriers to care among communities in New York City, nationally and globally. Additionally, Royalty Pharma is a founding corporate partner of Life Science Cares New York, which fights poverty and inequity in the city through education. Royalty Pharma has also made charitable contributions to the Leukemia and Lymphoma Society, a global leader in the fight against blood cancer.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 15 development-stage product candidates.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.